Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension

INTRODUCTION: In the event-driven GRIPHON randomised-controlled trial, the oral prostacyclin receptor agonist selexipag significantly reduced the risk of disease progression (composite primary endpoint of morbidity/mortality), compared with placebo, in patients with pulmonary arterial hypertension (...

Descripción completa

Detalles Bibliográficos
Autores principales: Galiè, Nazzareno, Gaine, Sean, Channick, Richard, Coghlan, J. Gerry, Hoeper, Marius M., Lang, Irene M., McLaughlin, Vallerie V., Lassen, Cheryl, Rubin, Lewis J., Hsu Schmitz, Shu-Fang, Sitbon, Olivier, Tapson, Victor F., Chin, Kelly M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799580/
https://www.ncbi.nlm.nih.gov/pubmed/34727317
http://dx.doi.org/10.1007/s12325-021-01898-1

Ejemplares similares

Ejemplares similares